Axial fat saturated post-gadolinium T1-weighted images of the lower cervical region and upper part of the chest before (a) and 3 months after (b) steroid therapy showing partial resolution of fascial thickening and contrast enhancement of the muscle fascia and i.m. parts.
With great interest we read the recently published article by Oda et al.
1 about fascial and muscle-related complications caused by cGVHD after allo-SCT. As musculoskeletal manifestations such as fasciitis are rare complications (5-year cumulative incidence 0.55%), these patients should be thoroughly evaluated to improve disease's management, classification criteria and therapeutic regimens.
1,2
We report a case of a 49-year-old male patient having received unrelated, HLA-matched allo-SCT after nonmyeloablative conditioning using radioimmunotherapy with Zevalin combined with Fludarabin/2 Gy TBI in November 2006 for recurrent follicular non-Hodgkin's lymphoma. The patient has been heavily pre-treated including cervical/mediastinal irradiation, intensive chemotherapy using VACOP-B and VIP-E regimens and auto-SCT after high-dose chemotherapy with BEAM.
In September 2008, he presented to our allogeneic transplantation outpatient clinic with pain, weakness and impaired mobility in the neck. The sternocleidomastoideus and trapezius muscles were found atrophic and indurated. Blood test showed no relevant clinical abnormalities apart from creatinine phospokinase (73 U/l), C-reactive protein (2.77 mg per 100 ml) and a low CYA level (42 ng/ml). Subsequently, an MRI of the cervical spine was performed, showing hyperintense signal on the fluid-sensitive sequences in cervical and cervicothoracal muscles bilaterally and along the corresponding fasciae. Correspondingly, the postcontrast fat-suppressed T1-weighted images showed periand i.m. enhancements corresponding to the thickening of both muscle fasciae and adjacent i.m. connective tissue septae (Figure 1 ). For the purposes of diagnosis, a biopsy of the trapezius muscle was performed. Histology showed patchy atrophy and interstitial fibrosis of the skeletal muscle with some CD3 þ T-lymphocytes and CD45 þ inflammatory cells (Figure 2 ). Based on these findings, musculofascial cGVHD was diagnosed and immunosuppressive therapy using 2 mg/kg steroids was started. In addition, tailored physical therapy was initiated. A control MRI in January 2009 after slow steroid taper, showed significant reduction in the fascial and especially i.m. enhancement with some persistent signal abnormalities. On clinical examination, we found slight improvement in mobility. However, reduction of the chronic fibrotic components will require long-term treatment.
The course of our patient nicely corresponds to the patients described by Oda et al. with a delay time to onset of musculofascial cGVHD of 690 days compared with 991 days. In analogy, C-reactive protein was slightly elevated only. No eosinophilia and normal creatinine phospokinase levels were found. Our patient also suffered from pulmonary involvement of cGVHD with bronchiolitis obliterans (BO), which was present in five of eight patients in the Japanese collective. MRI and pathological findings were similar.
As our patient received cervical and mediastinal irradiation therapy with 40 Gy in 1995 as first-line treatment of his lymphoma, one important differential diagnosis is post-irradiation fibrosis. Fibrosis in connective tissue after radiation therapy seems typically much earlier within 36-48 weeks. 3 However, it is now accepted that the inflammatory reaction in chronic musculofascial GVHD might be triggered in the fascia by local microlesions with subsequent wound-healing fibrosis. In addition, the role of irradiation in the induction of microtraumata with secondary wound healing and sclerosis has to be considered.
cGVDH involves a heterogeneous group of organ manifestations. Especially cutaneous forms like lichenoid or sclerodermoid GVHD are often difficult to differentiate from other fibrosing disorders of the fascia. 4 Moreover, in case of sclerodermoid GVHD, clinical assessment of the depth and extent of inflammation and/or collagenization are difficult. MR signal changes, however, represent a mixture of both increased inflammatory cells and collagenization. Our team published recently the results of a retrospective analysis of MRI findings in disabling musculocutaneous cGVHD. 5 In our opinion, MRI is a noninvasive imaging tool that may obviate invasive procedures for accomplishment of disease expansion and for distinction between skin manifestations, fasciitis and myositis in patients admitted for this disorder.
Therapy of these kinds of complications remains difficult. Extracorporeal or PUVA-photochemotherapy in addition to intensified systemic immunosuppression can improve sclerosis and prevent contractures. 6, 7 
